Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DuoGenic StemCells's Other Operating Expense for the
six
months ended in Jun. 2026 was NT$0.00 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-0.06 Mil.
DuoGenic StemCells's quarterly Other Operating Expense
declined
from Jun. 2025 (NT$0.00 Mil) to Dec. 2025 (NT$-0.06 Mil) but then
increased
from Dec. 2025 (NT$-0.06 Mil) to Jun. 2026 (NT$0.00 Mil).
DuoGenic StemCells's annual Other Operating Expense
stayed the same
from Dec. 2023 (NT$0.00 Mil) to Dec. 2024 (NT$0.00 Mil) but then
declined
from Dec. 2024 (NT$0.00 Mil) to Dec. 2025 (NT$-0.06 Mil).
DuoGenic StemCells Other Operating Expense Related Terms
DuoGenic StemCells Other Operating Expense Historical Data
* Premium members only.
The historical data trend for DuoGenic StemCells's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-0.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of NT$-0.06 Mil mean?
DuoGenic StemCells (ROCO:7607) has a Other Operating Expense of NT$-0.06 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on DuoGenic StemCells and its competitors.
Is DuoGenic StemCells' Other Operating Expense too high?
DuoGenic StemCells' current Other Operating Expense is NT$-0.06 Mil. Overall, DuoGenic StemCells has a GF Score™ of 25/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' Other Operating Expense compare to VRTX and REGN?
DuoGenic StemCells' Other Operating Expense of NT$-0.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on DuoGenic StemCells and its competitors. DuoGenic StemCells's current Other Operating Expense is NT$-0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$51.70, compared to a current price of NT$11.85 — trading 77.1% below its estimated fair value. The current Other Operating Expense is NT$-0.06 Mil. DuoGenic StemCells' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current Other Operating Expense is NT$-0.06 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?
Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued.
The current stock price of NT$11.85 is trading 77.1% below its estimated GF Value™ of NT$51.70.
GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.
Key valuation signals for ROCO:7607:
Other Operating Expense: NT$-0.06 Mil
GF Value™: NT$51.70 vs. price of NT$11.85 (77.1% below fair value)
No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
25GF Score
Get the complete analysis for ROCO:7607
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7607 has been successfully added to your 
